- Country: USA
- Summary: NIAID COMET™ Lunaphore ACD enables multiplex sequential immunofluorescence (multiplex seqIF™)-Brand Name
- UST Ref No: 126608861
- Deadline: 01 Oct 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: 75P00125Q00069-SB
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
Sources Sought (SS)
Title: COMET™ Lunaphore ACD enables multiplex sequential immunofluorescence (multiplex seqIF™)-brand nameID: 75P00125Q00069-SBPost Date: September 17, 2025Response Date: September 19, 2025, Amended to October 1, 2025Classification Code: 6640 - Laboratory Equipment and SuppliesNAICS: 325413 In-Vitro Diagnostic Substance Manufacturing
IntroductionThis is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability (foreign and domestic end products), capability of all qualified sources to perform a potential requirement.
Project SummaryThe National Institute of Allergy and Infectious Diseases (NIAID) Tissue Analysis Core (TAC) contributes to Vaccine Research Center (VRC) mission by characterizing pathogen and immune signatures at tissue level and in cellular in vitro system to better understand natural infection and strategies of intervention and vaccines To implement current imaging workflow, NIAID is seeking a spatial immunohistochemistry technology to reveal complex interactions at tissue level for infections, vaccines, and tumor studies bypassing the limitation of the number of fluorophores with high pixel resolution using only xy resolution.
Specifically, NIAID, TAC is seeking a COMET™ Lunaphore ACD enables multiplex sequential immunofluorescence (multiplex seqIF™).
The minimum technical requirements of the COMET™ Lunaphore (ACD) include:• Multiplex sequential immunofluorescence (multiplex seqIF™) • Performs 40-plex protocols per automated run• Compatible with FFPE and Frozen tissue slides• Compatible with all positive charged slides (standard histology) • Technology unlocked for the number of plex.• preserves sample morphology and epitope integrity by gently and efficiently removing antibodies and residues from the sample. This enables samples to be reused downstream for other applicatio... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINNIAID COMET™ Lunaphore ACD enables multiplex sequential immunofluorescence (multiplex seqIF™)-Brand Name - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | OFFICE OF THE ASSISTANT SECRETARY FOR ADMINISTRATION (ASA), a Government sector organization in USA, has announced a new tender for NIAID COMET™ Lunaphore ACD enables multiplex sequential immunofluorescence (multiplex seqIF™)-Brand Name. This tender is published on USARFP under UST Ref No: 126608861 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-10-01.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
